SOURCE: Bio-Rad Laboratories

April 02, 2007 08:00 ET

Bio-Rad Releases Epstein Barr Virus Kits for Use on the BioPlex 2200 System

Novel Automated Multiplexing Technology Streamlines EBV Patient Testing and Maximizes Laboratory Efficiency

HERCULES, CA -- (MARKET WIRE) -- April 2, 2007 -- Bio-Rad Laboratories, Inc. (AMEX: BIO) (AMEX: BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it has launched 2 Epstein Barr Virus (EBV) kits for use on its BioPlex® 2200 system, a diagnostic platform that employs multiplexing technology to analyze for multiple disease markers from a single patient sample.

"We are extremely pleased to offer our customers 2 new kits for EBV, including the only heterophile IgM assay available on an automated platform," said John Goetz, Vice President of Bio-Rad's Clinical Diagnostics Group. "The release of the BioPlex 2200 EBV IgG and IgM kits is another example of Bio-Rad's commitment to providing valuable tools that provide laboratories ways to improve testing methods, maximize efficiencies, and lower costs."

Each of the 2 kits provides for multiple results from a single patient sample. The IgG kit includes assays for EBV VCA, EBV NA-1, and EBV EA-D, and the IgM kit includes assays for EBV VCA and heterophile antibodies. By delivering results for 5 of the most clinically relevant antibodies, the BioPlex 2200 system enables laboratories to rapidly determine patient serological status on a fully automated and fully integrated random access platform.

About Bio-Rad

Bio-Rad Laboratories, Inc. (AMEX: BIO) (AMEX: BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 75,000 research and industry customers worldwide through its global network of operations. The company employs over 5,000 people globally and had revenues exceeding $1.2 billion in 2006. For more information, visit

Various statements made within this press release may constitute "forward-looking statements" for the purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company's expectation.

Contact Information

  • For more information contact:
    Tina Cuccia
    Corporate Communications Manager
    Bio-Rad Laboratories, Inc.
    Email Contact